O14744 (ANM5_HUMAN) Homo sapiens (Human)
Protein arginine N-methyltransferase 5 UniProtKBInterProSTRINGInteractive Modelling
637 aa; Sequence (Fasta) ; (Isoform 2; Isoform 4; Isoform 5; Isoform 3);
10 identical sequences: Pan troglodytes: K7B5I7, K7AYQ8; Gorilla gorilla gorilla: G3R5J7; Theropithecus gelada: A0A8D2K4A5; Papio anubis: A0A096N5H2; Macaca mulatta: H9FNP7; Macaca fascicularis: G8F670; Rhinopithecus roxellana: A0A2K6NY20; Rhinopithecus bieti: A0AAJ7M715; Carlito syrichta: A0A1U7TTX7
Available Structures
65 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| PRMT5 complex bound to covalent PBM inhibitor BRD6711 |
Heteromer Q9BQA1; | 100.0 | 4×QN4; 8×CL; 4×SFG; 8×GOL; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 2×MTA; 2×UNL; 4×GOL; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×UNL; 2×GOL; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×UNL; 2×GOL; | |||
| Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×JYX; 2×GOL; | |||
| PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound |
Heteromer Q9BQA1; | 100.0 | 1×CL; 1×NA; 1×EDO; 1×81X; 1×MTA; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA |
Heteromer Q9BQA1; | 100 | 1×MTA; 10×EDO; 1×GOL; 2×PEG; | |||
| Crystal Structure of the human PRMT5:MEP50 Complex |
Heteromer P62805; Q9BQA1; | 100 | 4×0XU; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×UNL; 2×GOL; | |||
| PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31) |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×85E; | |||
| PRMT5/MEP50 with compound 30 bound |
Heteromer Q9BQA1; | 100 | 1×97L; 1×MTA; | |||
| Human PRMT5 in complex with AZ compound 12 |
Heteromer Q9BQA1; | 100 | 4×A1H76; 4×MTA; 4×SO4; | |||
| Human PRMT5 in complex with AZ compound 28 |
Heteromer Q9BQA1; | 100 | 4×A1H73; 4×MTA; 4×SO4; | |||
| PRMT5/MEP50 crystal structure with sinefungin bound |
Heteromer Q9BQA1; | 100.0 | 1×SFG; | |||
| CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146 |
Heteromer Q9BQA1; | 100 | 1×K8H; | |||
| Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin |
Heteromer Q9BQA1; | 100 | 4×SFG; 4×5QJ; 16×GOL; | |||
| Human PRMT5 in complex with AZ compound 21 |
Heteromer Q9BQA1; | 100 | 4×A1H8B; 4×MTA; 4×SO4; | |||
| Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide |
Heteromer P62805; Q9BQA1; | 100 | 4×MTA; | |||
| Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin |
Heteromer Q9BQA1; | 100 | 1×SFG; 1×3XV; 3×GOL; | |||
| Human PRMT5 in complex with AZ compound 1 |
Heteromer Q9BQA1; | 100 | 4×A1H8A; 4×MTA; 4×SO4; | |||
| Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin |
Heteromer Q9BQA1; | 100 | 1×SFG; 1×4Z2; 1×GOL; | |||
| Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin |
Heteromer Q9BQA1; | 100 | 4×SFG; 4×5QL; 8×GOL; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×UNL; 2×GOL; 1×CL; | |||
| Crystal structure of PRMT5:MEP50 with Compound 10 and SAM |
Heteromer Q9BQA1; | 100 | 4×SAM; 4×5QK; 8×GOL; | |||
| PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800 |
Heteromer Q9BQA1; | 99.84 | 4×ZR4; | |||
| PRMT5:MEP50 complexed with adenosine |
Heteromer Q9BQA1; | 100.0 | 4×ADN; | |||
| PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34 |
Heteromer Q9BQA1; | 100 | 6×EDO; 1×WFS; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA and TNG908 |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×A1AAV; 4×PEG; 2×EDO; 6×CL; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 23 |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×A1AAT; 20×EDO; | |||
| PRMT5-MEP50 Complexed with SAM |
Heteromer Q9BQA1; | 100 | 15×EDO; 2×CL; 1×SAM; | |||
| HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 2×GOL; 1×UNL; | |||
| Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound |
Heteromer Q9BQA1; | 100 | 1×PWL; 1×MTA; 3×PEG; 2×EDO; | |||
| PRMT5:MEP50 complexed with inhibitor PF-06939999 |
Heteromer Q9BQA1; | 100.0 | 4×ZR1; | |||
| PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72 |
Heteromer Q9BQA1; | 100 | 4×EDO; 1×WFV; | |||
| PRMT5/MEP50 with compound 29 bound |
Heteromer Q9BQA1; | 100 | 1×97X; 1×MTA; | |||
| Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin |
Heteromer Q9BQA1; | 100 | 4×SFG; 4×5QH; 8×GOL; | |||
| PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4 |
Heteromer Q9BQA1; | 100 | 1×WFM; 10×EDO; 3×CL; 2×PEG; | |||
| CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882 |
Heteromer Q9BQA1; | 100 | 1×K8N; | |||
| PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999 |
Heteromer Q9BQA1; | 99.84 | 1×ZR1; | |||
| PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8 |
Heteromer Q9BQA1; | 100.0 | 1×QKY; 1×EDO; 1×GOL; | |||
| PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1 |
Heteromer Q9BQA1; | 100 | 8×EDO; 1×LB3; | |||
| Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors |
Heteromer Q9BQA1; | 100 | 1×CUX; 1×DMS; 7×EDO; | |||
| Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound |
Heteromer Q9BQA1; | 100 | 1×PWX; 1×MTA; | |||
| PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×85K; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 1 |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×A1AAS; 1×EDO; 1×CL; | |||
| HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound |
Heteromer Q9BQA1; | 100.0 | 1×PJ0; 1×MTA; 1×SO4; 2×EDO; 3×PEG; 2×CL; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 24 |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×A1AAU; 1×GOL; 2×CL; | |||
| PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound |
Heteromer Q9BQA1; | 100 | 1×NXF; 1×MTA; | |||
| PRMT5:MEP50 complexed with inhibitor PF-06855800 |
Heteromer Q9BQA1; | 100.0 | 4×ZR4; | |||
| PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9) |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×84W; | |||
| Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 28 |
Heteromer Q9BQA1; | 100 | 1×MTA; 1×A1AAR; 2×CL; 1×GOL; | |||
| Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with a… |
Heteromer Q9BQA1; | 100 | 4×F5J; | |||
| Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound |
Heteromer Q9BQA1; | 100.0 | 1×PUI; 1×MTA; 3×PEG; 3×CL; | |||
| CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437 |
Heteromer Q9BQA1; | 100 | 1×U6K; 1×EPE; 3×EDO; 1×PEG; | |||
| Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM |
Heteromer Q9BQA1; | 100 | 1×SAM; 1×3XV; 1×GOL; | |||
| AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives anti-tumor activity preclinically… |
Heteromer Q9BQA1; | 100 | 2×GOL; 1×DMS; 1×A1ATH; 1×MTA; | |||
| PRMT5 bound to the PBM peptide from pICln |
Heteromer P54105; Q9BQA1; | 100 | 4×SFG; 4×ACE; | |||
| Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH |
Heteromer Q9BQA1; | 100 | 1×SAH; 1×3XV; | |||
| Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom |
Heteromer Q9BQA1; | 100.0 | ||||
| CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988 |
Heteromer Q9BQA1; | 100.0 | 4×YJG; | |||
| Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of hu… |
Heteromer Q9BQA1; | 100 | 1×P2R; 1×MTA; | |||
| PRMT5 bound to PBM peptide from Riok1 |
Heteromer Q9BQA1; Q9BRS2; | 100 | 4×SFG; | |||
| PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a |
Heteromer Q9BQA1; | 100.0 | 1×QL1; | |||
| Structure of the methylosome-Lsm10/11 complex |
Heteromer P83369; Q61189; Q9BQA1; | 100.0 | 4×ADN; | |||
| Crystal structure of the PRMT5 TIM barrel domain in complex with RioK1 peptide |
Heteromer Q9BRS2; | 100.0 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5fa5.3.A | monomer | 0.92 | 100.00 | |||
4 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 5fa5.3.A | monomer | 0.92 | 99.34 | |||
| Isoform 3 | 5fa5.3.A | monomer | 0.89 | 99.29 | |||
| Isoform 4 | 5fa5.3.A | monomer | 0.84 | 98.90 | |||
| Isoform 5 | 5fa5.3.A | monomer | 0.90 | 100.00 | |||